FGF21 and metabolic dysfunction-associated steatotic liver disease: The randomized placebo-controlled trial EFFECT-II study demonstrated beneficial effects of the SGLT2i dapagliflozin on hepatocyte injury biomarkers, as well as plasma concentrations of fibroblast growth factor 21 (FGF21) in patients with NAFLD associated with T2D, which suggests reductions in cellular damage and fibrosis [30].